AAAP Advanced Accelerator Applicatio

37.25
+0  (0%)
Previous Close 37.11
Open 37.24
Price To book 8.48
Market Cap 1.46B
Shares 39,278,000
Volume 65,971
Short Ratio 3.06
Av. Daily Volume 120,087

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016
Apoptosis
Necrosis
Phase 2 initiated September 2016
Annexin V-128
Early Breast Cancer
Positive opinion by EMA released in October 2016.
Somakit-TOC
Neuroendocrine cancers
PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016.
Lutathera
Inoperable progressive midgut NETs
Approved June 1, 2016.
Somakit-TATE
Neuroendocrine tumor diagnosis
Ongoing
Annexin V-128
Rheumatoid arthritis and ankylosing spondylitis

Latest News

  1. Investor Network Invites You to the Advanced Accelerator Applications Year-End 2016 Earnings Conference Call and Webcast Live on Thursday, March 23, 2017
  2. Biotech firm says it’s closing in on the cancer that killed Steve Jobs
  3. Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23
  4. Calithera Biosciences (CALA) Rises: Stock Moves Up 19.3%
  5. New Strong Buy Stocks for March 9th
  6. Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS
  7. Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs
  8. Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
  9. Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
  10. ETFs with exposure to Advanced Accelerator Applications SA : January 11, 2017
  11. Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA
  12. Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference
  13. Advanced Accelerator Applications downgraded by JMP Securities
  14. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  15. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  16. Is Advanced Accelerator Application SA (ADR) (AAAP) a Good Stock to Buy?
  17. Is Herc Holdings Inc. (HRI) Worthy of Your Portfolio?
  18. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  19. Advanced Accelerator Applications SA :AAAP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  20. Edited Transcript of AAAP earnings conference call or presentation 28-Nov-16 9:30pm GMT